.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,256,310

« Back to Dashboard

Claims for Patent: 7,256,310

Title:Levalbuterol salt
Abstract:Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
Inventor(s): McGlynn; Paul (Marlborough, MA), Bakale; Roger (Shrewsbury, MA), Sturge; Craig (Falmouth, CA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:10/728,873
Patent Claims: 1. Levalbuterol L-tartrate.

2. Levalbuterol L-tartrate as claimed in claim 1, which is in crystalline form.

3. Levalbuterol L-tartrate as claimed in claim 2, containing from 0.3 to 0.7% ethanol.

4. Levalbuterol L-tartrate as claimed in claim 2, which is in micronized form.

5. Levalbuterol L-tartrate as claimed in claim 4, which is in the form of needle-like particles.

6. A pharmaceutical composition, which comprises levalbuterol L-tartrate as claimed in claim 1, together with a pharmaceutically acceptable carrier.

7. A pharmaceutical composition as claimed in claim 6, which is an aerosol formulation adapted for administration using a metered dose inhaler, the aerosol formulation comprising levalbuterol L-tartrate in crystalline form and a propellant.

8. A pharmaceutical composition as claimed in claim 7, in which the propellant is 1,1,1,2-tetrafluoroethane.

9. A pharmaceutical composition as claimed in claim 7, which further comprises a surfactant.

10. A pharmaceutical composition as claimed in claim 7, which further comprises a co-solvent.

11. A pharmaceutical composition as claimed in claim 10, in which the co-solvent is ethanol.

12. An aerosol formulation adapted for administration using a metered dose inhaler, the aerosol formulation comprising levalbuterol L-tartrate crystals in the form of micronized, needle-like particles, and a propellant.

13. An aerosol formulation as claimed in claim 12, in which the propellant is 1,1,1,2-tetrafluoroethane.

14. An aerosol formulation as claimed in claim 13, which further comprises from 2 to 6% by weight of ethanol as a co-solvent.

15. A metered dose inhaler comprising a canister containing an aerosol formulation as defined in claim 7, a metering valve and a valve stem.

16. A metered dose inhaler comprising a canister containing an aerosol formulation as defined in claim 12, a metering valve and a valve stem.

17. A pharmaceutical composition as claimed in claim 6, which is adapted for administration using a dry powder inhaler or insufflator.

18. A process for the preparation of levalbuterol L-tartrate crystals, which comprises combining a solution of levalbuterol with a solution of L-tartaric acid and recovering levalbuterol L-tartrate crystals.

19. A process as claimed in claim 18, in which the solvent in each solution comprises ethanol.

20. A process as claimed in claim 18, in which the crystallization conditions are selected so as to provide crystals having a length of 10 to 50 microns and a width of 0.2 to 4 microns.

21. A process as claimed in claim 18, in which the levalbuterol has been prepared by hydrogenating R-benzylalbuterol in the presence of palladium on carbon.

22. A process as claimed in claim 21, in which the hydrogenation has been conducted under conditions selected to effect conversion of at least 99.9% of the R-benzylalbuterol without over reduction of other functional groups.

23. A process as claimed in claim 18, in which the crystals are dried and micronized, the crystallization and drying conditions being selected so as to afford needle-like particles after micronization.

24. A process for the preparation of levalbuterol L-tartrate crystals, which comprises combining a solution of levalbuterol with a solution of L-tartaric acid, recovering levalbuterol L-tartrate crystals, and then drying and micronizing the recovered crystals, the crystallization and drying conditions being selected so as to afford needle-like particles after micronization.

25. Levalbuterol L-tartrate crystals obtained by the process of claim 18.

26. Levalbuterol L-tartrate crystals obtained by the process of claim 24.

27. A method of effecting bronchodilation in a patient in need of treatment, which comprises administering to said patient an effective amount of levalbuterol L-tartrate.

28. A method as claimed in claim 27, in which micronized crystals of levalbuterol L-tartrate are administered by inhalation using a metered dose inhaler.

29. A method as claimed in claim 28, in which the micronized crystals of levalbuterol L-tartrate are in the form of needle-like particles.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc